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Abstract   
Background: We know from previous studies that faecal incontinence (leakage syndrome) 
has a negative effect on self-assessed quality of life (QOL) and social functioning among 
gynaecological cancer survivors treated with external pelvic radiotherapy. There is, however, 
a lack of knowledge regarding how other radiation-induced bowel syndromes affect QOL in 
these survivors.  
Aim: To investigate the association between the adverse effects of radiation therapy 
experienced by gynaecological cancer survivors and their QOL.  
Methods: Previous studies identified 28 gastrointestinal symptoms that reflect decreasing 
health among gynaecological cancer survivors after external pelvic radiotherapy measured 
two to 15 years after treatment. The 28 symptoms were grouped by the original researchers 
into five radiation-induced survivorship syndromes (urgency syndrome, leakage syndrome, 
excessive gas discharge, excessive mucus discharge and blood discharge) by using factor 
analysis. A patient-reported outcome measures (PROMs) questionnaire was sent to 623 
survivors and 344 matched population-based controls. Based on six questions chosen from the 
questionnaire, different QOL outcomes were measured: Self-assessed QOL, feeling sad or 
depressed, worry or anxiety, psychological well-being, self-assessed physical health and self-
esteem. 
Results: The participation rate for cancer survivors was 76% and for the control group 72%. 
Data show that all five radiation-induced survivorship syndromes contribute to lower self-
assessed QOL, lower psychological well-being, and have negative effects on physical health 
and self-esteem compared to the control group.  No significant elevated risk for depression or 
anxiety was seen. 
Conclusion: Gynaecological cancer survivors with radiation-induced survivorship syndrome 
have a lower self-assessed QOL. Living with urgency, leakage, excessive gas, excessive 
mucus or blood in faeces is associated with greater occurrence of adverse psychological 
consequences in survivors than women in the control group.  
Keywords: Gynaecological cancer; Psychological well-being; Quality of life; Radiation-
Induced Survivorship Syndromes; Bowel toxicity 
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Background 
Cancer is one of the leading causes of morbidity and mortality worldwide. In Sweden, 
approximately 2800 women develops gynaecological cancer every year and approximately 
30,000 women are gynecological cancer survivors (1, 2). There are five main types of cancer 
that occur in the female reproductive system: cervical, ovarian, endometrial, vaginal, and 
vulvar cancer (3). The most common gynaecological cancer type is endometrial cancer. In 
addition, there are types that are much less common such as uterine sarcoma and fallopian 
tube cancer. Surgery, radiotherapy and chemotherapy are different methods used for 
treatment. The choice of treatment depends mainly on the type and stage of cancer. Most 
women with gynaecological cancer receive pelvic radiotherapy, and it is estimated that across 
the developed world, between 150 000 to 300 000 people undergo pelvic radiotherapy yearly 
and that 80% of these will develop gastrointestinal symptoms during treatment (4). The first 
use of radiotherapy in cancer treatment occurred in 1896, and only one year later damaging 
effects to the intestine caused by radiation were described (5). Since radiation is used as 
treatment for patients with pelvic cancer more often for than any other tumor site, 
understanding the effects of radiation in the pelvis is of great importance (6). 
 
Pelvic radiation disease is defined as changes that arise in healthy tissues as a result of 
radiation delivered to a tumour in the pelvis (6). Gastrointestinal symptoms can vary from 
mild to very severe. These symptoms have been divided into two groups, acute and late onset. 
Acute changes are seen until 90 days after last treatment and late changes occurring thereafter 
(7). Acute changes in the gastrointestinal tract are mediated by cytotoxic effect of radiation on 
fast growing epithelium, and this effect is amplified by inflammatory processes (7). These two 
mechanisms increase the concentration of free radicals and cause damage to DNA (8). As 
concerns late-onset symptoms, reactions that began in the acute phase are amplified leading to 
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loss of stem cells, incomplete healing, and ischemia. All of these may cause intestinal fibrosis 
(5).  
 
Chronic radiation enteritis typically develops between 18 months and 6 years following 
radiotherapy, although it has been reported as appearing as late as 15 years after treatment (9). 
Up to one-fifth of patients receiving pelvic radiotherapy develop chronic radiation enteritis, 
which is associated with increased morbidity and mortality (9). 
 
Radiation enteritis has multifactorial causes, including the method and dose of radiation 
delivered, genetic background, and environmental factors such as smoking and diet. However, 
the extent to which each risk factor contributes to toxicity is unknown (5).  
 
Mechanisms involved in radiation-induced gastrointestinal toxicity are similar to mechanisms 
involved in Inflammatory Bowel Disease (IBD), the two main forms of which are Crohn’s 
disease and ulcerative colitis (5). Clinically, both are often characterised by symptoms such as 
diarrhoea, rectal bleeding and malabsorption. Histologically, both display pronounced 
infiltration of innate and adaptive immune cells into the lamina propria, and this is associated 
with epithelial destruction and mucosal ulceration (5). Ulcerative colitis tend to be limited to 
the mucosa while Crohn’s disease and radiation-induced gastrointestinal toxicity tend to be 
transmural (5). Radiation-induced gastrointestinal toxicity and IBD share some inflammatory 
mechanisms. Both have upregulated gene expression and secretion of pro-inflammatory 
cytokines IL-1b, TNFa and TGF-b (7, 10). Inflammation seen in intestinal toxicity is induced 
by ionizing radiation; the cause for IBD is less well established (11). Cancer survivors treated 
by radiotherapy have a reduced diversity of the Firmicutes and Bacteroidetes, two bacteria 
phyla that have an important role in controlling intestinal inflammation. The same kind of 
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depletion has been seen among patients with IBD (7, 12). These patients also have an 
increased number of pathogenic bacteria such as enterobacteriaceae (13, 14). An imbalance 
between the bacteria phyla involved in intestinal homeostasis and an increase in pathogens is 
the cause of dysbiosis. Even though both diseases share many similiarites, radiaton-induced 
gastrointestinal toxicity receive less attention from healthcare and fundings spent on research 
(15). 
 
In a study conducted by Steineck et al. (16), gynaecological cancer survivors were given a 
questionnaire two to 15 years after they had undergone pelvic radiotherapy. A total of 28 
gastrointestinal symptoms were reported by survivors; these symptoms may be grouped into 
five syndromes through factor analysis (Figure 1). These symptoms are manifestations of five 
different radiation-induced survivorship syndromes: Urgency syndrome, leakage syndrome, 
excessive gas discharge, excessive mucus discharge, and blood discharge (16). In each 
syndrome, one symptom predominates but can be accompanied by other less prevalent 
symptoms. For example, patients with urgency syndrome mainly have trouble with defecation 
urgency but may also complain of stool leakage, gas, mucus or blood discharge in feces. 
Seventy-four percent of survivors affected with faecal incontinence (leakage syndrome) 
reported low to moderate QOL and one third of them reported that they would have refrained 
from radiation treatment if they had been fully aware of the negative consequences (17).  
 
Up to 90% of cervical cancer survivors who had pelvic radiotherapy may have permanent 
changes in their bowel habits and up to 50% state that these symptoms negatively impact their 
QOL (18). Fecal urgency, tenesmus, and fecal incontinence have the largest negative impact 
on QOL (18). The specific symptoms that are most bothersome vary by disease site; 
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symptoms related to bowel problems are most important for endometrial cancer patients while 
body image is more important for cervical cancer patients (19).  
 
Availiable treatment methods are either non-pharmacological or pharmacological 
interventions. 
Non-pharmacological interventions 
Cancer rehabilitation aims to improve quality of life following cancer. The World Health 
Organisation recommends that rehabilitation includes: “Identification of a person’s problems 
and needs, relating the problems to relevant factors of the person and the environment, 
defining rehabilitation goals, planning and implementing the measures, and assessing the 
effects” (20). 
 
A systematic review summarised the effects of psychosocial interventions in women with 
gynaecological cancers on their QOL outcomes (21). Twenty-two studies with 1926 
participants were included. Eighteen were RCTs, two cohort studies and one intervention. 
Education about symptom distress, information provided about cancer, and coping training 
showed benefits for reducing psychological distress. Individual and group consuelling 
interventions reduced symptoms of depression and anxiety and improved patient’s attitudes 
toward their health care. Cogntive-behavioural therapy improved self-esteem and body image. 
Relaxation techniques and guided imagery led to reductions in symptom-related body 
discomfort (21). 
 
Reviews of exercise studies in patients with cancer have concluded that exercise reduces 
fatigue and improves QOL (22). Studies have led to a hypothesis that endometrial cancer 
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survivors who are able to perform 150 min/week of physical activity may be protected from 
negative effects of higher BMI on QOL (23). 
Pharmacological interventions 
Cancer survivors with gastrointestinal symptoms are recommended to treat symptoms by 
using bulk-forming agents or anti-diarrheal agent and incontinence products. In more severe 
cases pancreatic enzymes supplements, bile acid sequestrant or antibiotics might be required 
(24).  Erythropoietin treatment used for CRF caused by anaemia can improve a patient’s 
fatigue level and QOL (25). 
 
Figure 1 Results from a modified factor analysis showed that 28 frequent gastrointestinal 
symptoms reported could be grouped into five syndromes that can be manifestations of five 
different radiation-induced survivorship syndromes; Urgency syndrome (red), leakage 
syndrome (green), excessive gas discharge (light blue), excessive mucus discharge (purple) 
and blood discharge (black). Constipation (blue) was not statistically significant (P>0,001, 
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Mann-Whitney test) and was thus not included as a radiation-induced survivorship syndrome.  
Reproduced from Steineck et al. (9). 
 
 
 
 
Aims  
• To investigate the association between five radiation-induced survivorship syndromes 
and six different QOL outcomes among gynaecological cancer survivors.  
• Compare physical and mental health among cancer survivors and women in the 
control group. 
• Identify specific symptoms resulting from late treatment toxicity that have the greatest 
effect on QOL. 
Material and Methods   
Study population 
The study carried out by Dunberger and co-workers began by selecting a cohort of 1800 
women with gynecological malignancy were treated with external pelvic radiotherapy 
between 1991 and 2003 at Radiumhemmet, Karolinska University Hospital in Stockholm and 
at Jubileumskliniken, Sahlgrenska University Hospital in Gothenburg (Figure 2). An 
introduction letter was sent to 823 eligible survivors after excluding patients who did not meet 
one or more of the following eligibility criteria: deceased at follow up, born before 1927, 
could not understand or read Swedish, had recurrence of disease and did not receive pelvic 
radiotherapy. In the end, 623 (76%) survivors were included in the study (17). 
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Figure 2 Flowchart of study population: Cancer survivors and control group with inclusion 
and exclusion criteria. 
 
A control group was created consisting of 486 women randomly recruited from Swedish 
Population Registry matched by age and place of residence to the survivor group. An error in 
the matching procedure led to an age difference between control and cancer survivors, this 
was adjusted for in all analyses. Exclusion criteria were previous pelvic radiotherapy and that 
they could not understand or read Swedish. In the end, 344 (72%) controls were included in 
the study (17).  
Data collection procedures 
Between January and October 2006 all gynecological cancer survivors and population based 
controls received an introductory letter and a phone call. All who confirmed that they were 
willing to participate by giving oral consent received the questionnaire. The longest interval 
between 2006 and the time of treatment was 15 years, and the shortest two years. Each 
questionnaire contained a number to enable identification while maintaining anonymity. All 
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actions were taken by a neutral third-party secretariat (26); none of the health-care 
professionals involved had access to the data. The results from the questionnaire were coded 
and transferred to data entry and validation using program Epi-Data (www.epidata.dk).  
Selection of questions 
The questionnaire consisted of 351 questions and contained eight parts: Part 1 covered 
demographic data, information about disease and its treatment. Part 2 dealt with self-assessed 
depression and anxiety, QOL, physical health and social functioning. Parts 3 to 8 covered 
physical symptoms, intercurrent diseases and sexual health (17). 
 
Based on six questions chosen from the questionnaire, different QOL outcomes were 
measured. All six questions had answering categories using a Visual-digital scale ranging 
from 1-7. The measurement of QOL was based on answers to the question “How would you 
evaluate your quality of life during the past six months?” where 1 signified no QOL and 7 
best QOL with a cutoff point of 1-3 classified as low self-assessed QOL. (Appendix) 
 
The questions “How would you evaluate your mental health during the past six months?” and 
“How would you evaluate your physical health during the past six months?” were used in 
determining the survivor’s mental and physical health. The question “How would you 
evaluate your self-esteem during the past six months?” was used to obtain information about 
the subjective emotional evaluation of the subjects. Low psychological well-being, low self-
assessed poor physical health and low self-esteem were denoted by answers in the interval 1-3 
(Appendix). 
 
The following two questions were used to determine the survivors’ mood: “Have you felt sad 
or depressed during the past six months?” and “Have you felt worry or anxiety during the 
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past six months?” The end points of the scales for these questions were 1 for  ”Never” and 7 
for ”All the time”. Feeling sad or depressed or experiencing worry or anxiety were denoted by 
answers in the interval 5-7 (Appendix). 
Statistical methods  
To assess bivariate relationships between QOL outcomes including self-assessed QOL, 
feeling sad or depressed, worry or anxiety, psychological well-being, self-assessed physical 
health, self-esteem and radiation-induced survivorship syndromes, we used log-binomial 
regression analysis. Relative risk is used as a measure of the strength of the link between QOL 
outcome and radiation-induced survivorship syndrome with 95% confidence interval (CI). 
Results were age-adjusted using log-binomial regression analysis. Statistical analyses were 
performed using SAS 9.4 for Windows (SAS Institute Inc., Cary, NC, USA). The relative risk 
was considered statistically significant when 95% confidence interval did not contain the 
reference value, 1.00. 
Ethics  
Informed consent was obtained from the study participants. Each questionnaire are coded and 
not possible to trace. The Regional Ethical Review Board approved of the study protocol 
(2005/1425-31/4), Stockholm, Sweden (16).  
Results  
Demography 
Clinical characteristics of cancer survivors and controls are presented in table 1. Mean age 
among survivors are 67 years and among control women 58.5 years. In the survivor group 
most women are between 70-80 years old, in a marriage or living with a partner. 243 
survivors with cardiovascular co-morbidities in comparison to 96 women in control group.  
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The most common gynaecological cancer was endometrial cancer (58%) followed by cervical 
cancer and ovarian cancer. Most survivors received both surgery and radiotherapy treatment 
564 of 623 (91%). A total of 340 women received additional brachytherapy, 114 women 
additional brachytherapy and chemotherapy, and 63 women additional chemotherapy. 
Surgical procedures consisted of total hysterectomy, bilateral salpingoophorectomy with or 
without omentectomy. 
 
In the group treated with radiotherapy alone, 26 of 59 women received external beam 
radiotherapy (EBRT) and brachytherapy, 23 women received EBRT, brachytherpy and 
chemotherapy, 8 women received EBRT and chemotherapy, and 2 women only EBRT.  
 
All cancer survivors received EBRT using a linear accelerator delivering an energy varying 
between 6 and 50 megavoltage (MV) photons. The dose of radiotherapy used as adjuvant 
therapy was between 40 and 50 Gy (1,6-2,0 Gy per fraction, 5d a week). The mean dose given 
to the women who had only radiotherapy was 54 Gy (39,6-70 Gy).  
 
Before 1996, a two-field technique was used and from 1996 a four-field box technique 
became the standard technique. In total, 503 (81%) survivors had brachytherapy and 208 
(33%) received chemotherapy as an adjuvant treatment.  
 
A total of 421 of these 623 (68%) of cancer survivors live with radiation-induced survivorship 
syndrome. Among the control women 128 of 344 (37%) experienced symptoms resembling 
radiation-induced survivorship syndrome (unpublished data). 
 
 
 15 
Table 1 Demographics and clinical characteristics of cancer survivors and control group 
Percentage may not total 100 because of rounding. 
Characteristics  
Cancer 
survivors 
Control 
group 
n = 623 (%) n = 344 (%) 
Age 
29–39 15 (2) 23 (7) 
40–49 49 (8) 72 (21) 
50–69 94 (15) 80 (23) 
60–69 223 (36) 75 (22) 
70–80 242 (39) 92 (27) 
Mean age (range) 67  58.5 
Not stated - 2 (<1) 
Marital status 
Married or living with a partner 355 (57) 220 (64) 
Has a partner but lives alone 36 (6) 22 (6) 
Widow 81 (13) 37 (11) 
Single 149 (24) 65 (19) 
Not stated 2 (<1) - 
Level of education 
Elementary school 194 (31) 69 (20) 
Secondary school 238 (38) 146 (42) 
Collage/university 190 (30) 127 (37) 
Not stated 1 (<1) 2 (<1) 
Employment status 
Student 6 (1) 2 (1) 
Unemployed 14 (2) 6 (2) 
Employed 204 (33) 188 (55) 
Housewife, other 12 (2) 5 (1) 
On sick leave  11 (2) 10 (3) 
Disability pension 55 (9) 15 (4) 
Retired 318 (51) 117 (34) 
Not stated 3 (<1) 1 (<1) 
Smoking 
Current smoker 141 (23) 88 (26) 
Former smoker 190 (31) 108 (32) 
Never smoked 278 (46) 146 (43) 
Not stated 14 (2) 2 (<1) 
Exercise 
Never 72 (12) 20 (6) 
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Characteristics  
Cancer 
survivors 
Control 
group 
n = 623 (%) n = 344 (%) 
At least once a month 84 (13) 59 (17) 
At least once a week 450 (72) 262 (76) 
Not stated 17 (3) 3 (1) 
Body Mass Index 
<18.5 (underweight) 17 (3) 5 (2) 
18.5–24.9 (normal weight) 268 (46) 163 (50) 
25.0–29.9 (overweight) 201 (34) 116 (35) 
>30.0 (obese) 99 (17) 43 (13) 
Not stated 38 (6) 17 (5) 
Intercurrent diseases 
Cardiovascular disease 243 (40) 96 (28) 
Diabetes mellitus 54 (9) 17 (5) 
Lung disease 37 (6) 12 (3) 
Diagnosis (ICD 10)     
Endometrial cancer (C54) 363 (58) Not applicable 
Cervical cancer (C53) 147 (24)   
Ovarian cancer (C56) 49 (8)   
Uterine sarcoma (C49) 30 (5)   
Vaginal cancer (C52) 14 (2)   
Fallopian tube cancer (C57) 14 (2)   
Vulvar cancer (C51) 6 (1)   
Treatment modality     
Surgery and EBRT, total 564 (91) Not applicable 
+ Brachytherapy 340 (55)   
+ Brachy- and chemotherapy 114 (18)   
+ Chemotherapy 63 (10)   
Surgery and radiotherapy alone 47 (8)  
EBRT alone, total 59 (10)   
+ Brachytherapy 26 (4)   
+ Brachy- and chemotherapy 23 (4)   
+ Chemotherapy 8 (1)  
Radiotherapy alone 2 (<1)  
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Association between radiation-induced survivorship syndromes and QOL outcomes 
The data show that all five radiation-induced survivorship syndromes are associated with 
lower self-assessed QOL, lower psychological well-being, and that all have a more negative 
effect on physical health and self-esteem than seen in the control group (Figure 3A, for more 
detailed information see the supplementary table). All radiation-induced survivorship 
syndrome increases risk for having lower QOL and poor physical health about three times 
greater than in control women.  All radiation-induced survivorship syndromes except excess 
mucus discharge (RR 1.6) result in a two times higher risk for the survivors to have reduced 
psychological well-being. About two to three times increased risk for having low self-esteem.  
No significant elevation in risk for being depressed or having anxiety was observed.  
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The highest relative risks for adverse change among survivors with blood discharge were for 
self-assessed poor physical health, RR 3.7 (95% CI: 2.2-6.2).  
The greatest effect on self-assessed low QOL, RR 3.3 (95% CI: 1.9-5.9) is seen among 
survivors with blood discharge. Highest relative risks for adverse change among survivors 
with blood discharge were for self-assessed poor physical health, RR 3.7 (95% CI: 2.2-6.2). 
 
A separate analysis intended to elucidate the relationships between survivors and controls 
complaining mainly of one dominant symptom (Figure 3B). Living with one dominant 
symptom such as urgency without also experiencing any other component of leakage 
syndrome, blood discharge, excessive mucus discharge or excessive gas discharge is rather 
rare. No statistical significance is seen between the two groups. Group size varying from 
around 10 women with excessive gas discharge, excessive mucus discharge, leakage or blood 
discharge to 40 women with urgency.  
 
There are about 200 women in the group who did not report experiencing radiation-induced 
survivorship syndromes. Relative risks for each QOL outecome overlaps 1.00 and thus these 
women do not show any difference in QOL outcomes compared to the control women (Figure 
3C). 
Discussion  
All five radiation-induced survivorship syndromes are associated with lower self-assessed 
QOL, lower psychological well-being, and each syndrome have a negative effect on physical 
health and self-esteem compared to population based control group. Each radiation-induced 
survivorship syndrome increases the risk for having lower QOL and physical health by a 
factor of three compared to the control women. The highest relative risks among survivors 
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with blood discharge for experiencing radiation-induced survivorship syndrome concern self-
assessed poor physical health and self-assessed low QOL. No significant elevation in risk is 
seen for depression or anxiety.  
 
Treatment modality affects long-term QOL in gynaecological cancer patients. Those patients 
who undergo relatively more radical surgery and those patients receiving radiotherapy have 
the most persistent bowel dysfunction many years after treatment of any of the survivors (18). 
In a study that focused on psychosocial problems among women with cervical cancer 
receiving EBRT with or without brachytherapy, depression and worry were initially high but 
decreased to the level of controls after six months. Psychosocial problems affecting QOL in 
cervical cancer surviviors include mood and stress disorders, body image and fear of 
recurrence (18). In comparison with results found in this report the level of depression or 
anxiety is not affected by the intensity of the radiation-induced survivorship syndrome. 
Gynaecological cancer survivors were followed two-15 years after treatment, if they felt 
depressed or worry initially were not documented and thus difficult to evaluate. 
 
A literature review by Nout et al. summarized studies about patient-reported outcome mesures 
(PROMs) and QOL in women with gynecologic malignancies who were treated with pelvic 
radiotherapy and found that endometrial cancer survivors had statistically significant higher 
rates of diarrhea and fecal leakage than any of the others (20). This limited the daily activities 
of this group and they thus had lower physical and role-physical functioning even 15 years 
after treatment (20). Role-physical functioning was concerned with job-related limitations and 
limitations on the ability of the women to do housework (27). Van de poll-Franse and 
colleagues conducted the largest retrospective health-related QOL study yet made among 
patients with endometrial cancer. Irradiated patients scored lower on all QOL scales compared 
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to normal population (28). Pelvic radiotherapy was independently linked with negative 
vitality and physical and social well-being (28). Park et al. reported in their case-control study 
including 860 cervical cancer survivors in Korea that cervical cancer survivors had 
significantly worse social functioning and bowel symptoms than seen in the national 
population. Anxiety about sexual performance was also seen among survivors (29). 
 
In a cross-sectional study with 235 patients, Carlsson et al. found that gynaecological cancer 
survivors previously treated with chemotherapy had more problems with fatigue and 
constipation than did those who did not receive chemotherapy. Patients treated with external 
radiotherapy and/or brachytherapy had significantly more problems with flatulence and 
diarrhoea than those who did not have such treatment (30). 
 
A population-based study from the Netherlands evaluated 666 endometrial cancer survivors 
and found a correlation between increased BMI and decreased physical function, decreased 
vitality, gastrointestinal problems and more fatigue symptoms (31). In the present study, 300 
(48%) of the total of 623 had a BMI above 25 and 285 of 623 (46%) had BMI under 25. Since 
there was no big difference between these two groups no conclusion can be drawn about the 
possible importance of BMI.  
 
In this study cardiovascular co-morbidities are more common among survivors. We know 
from before that cardiovascular disease and stroke have negative impacts on mental and 
physical health (32). Cardiovascular co-mobidites may be a contributing reason for decreased 
QOL seen among survivors, another difference between the two groups are survivors 
receiving a though cancer diagnosis which also can affect their QOL (33). 
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Cancer-related fatigue (CRF) is defined by the National Comprehensive Center Network 
(NCCN) as a persistent, subjective sense of tiredness related to cancer or cancer treatment that 
interferes with usual functioning. In contrast to the tiredness that might be felt by a healthy 
individual, CRF is a sensation of greater magnitude, disproportionate to activity and not 
relieved by rest. Fatigue is the most prevalent symptom of individuals with cancer who 
receive radiotherapy and cytotoxic chemotherapy (34). Jakobsson, Ahlberg, Taft et al. 
prospectively followed twenty-nine women undergoing pelvic radiotherapy for anal or uterine 
cancer (35). They examined if CRF is associated with radiation-induced intestinal injury, as 
assessed by both plasma citruline and diarrhea. Fatigue and diarrhea were assessed using 
PROMs questionnaire. Plasma citrulline is a biomarker of epithelial cell mass in the small 
bowel and has been shown to decrease during pelvic radiotherapy (36). The study indicates a 
link between CRF and intestinal injury during pelvic radiotherapy, CRF increased 
significantly (p <.001) and citrulline decreased significantly (p <0.001). The study included a 
small sample size and thus should be considered as a premliminary finding (35).  
 
CRF can help to explain why cancer survivors have lower QOL, reduced capacity of mental 
and physical health, low self-esteem and feelings of anxiety and depression. It is unknown 
whether fatigue is the cause of these symptoms or if fatigue is an effect of these factors (25). 
The pathophysiology of fatigue is not fully known (35). Many factors are thought to 
contribute to the development of CRF for example anemia, circadian rhythm disruption and 
an inflammatory reaction caused by the release of inflammatory mediators (37). One possible 
mechanism to the development of CRF during pelvic radiotherapy could be translocation of 
bacteria and other proinflammatory components into the systemic circulation, resulting in a 
cytokine-induced inflammatory reaction which in turn may elicit fatigue (35). 
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Strengths and limitations 
Strengths of the study on which this report is based on include large sample size and high 
participation rate. Returning filled-in questionnaires to a trial secretariat probably minimized 
risk of measurement errors and avoided interviewer-related bias.  
 
In the study the control group was younger on average than patients so statistical methods 
were used to adjust for this difference. The results are based on place and time specific and 
may not be able to apply for other settings. The upper age limit was 80 years and whether the 
results differ among the elderly is unknown. Some statistical analysis performed included 
small group sizes which resulted in a non-significant result, but it is important to remember 
the possibility that a non-significant result may actually be a real difference with a larger 
sample (38). 
Conclusions and Implications 
Gynaecological cancer survivors with radiation-induced survivorship syndrome have a lower 
self-assessed QOL. Living with urgency, leakage, excessive gas, excessive mucus or blood in 
faeces is associated with greater occurrence of adverse physical and psychological 
consquences in survivors than women in the control group. 
Future research 
New knowledge and skills learnt from clinical research and experience improve treatment 
methods for curing patients. Even though the treatment is much better today, we still lack 
much of the knowledge we need, to be able to prevent all side-effects. We need in the future 
to develop more advanced prevention, alleviation, and treatment methods for our present 
cancer survivors who suffer from radiation-induced survivorship syndromes.  
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Populärvetenskaplig sammanfattning 
Att överleva cancer men att leva med följdsjukdomar En studie om livskvalitet och 
psykisk hälsa hos gynekologiska canceröverlevare efter strålbehandling 
I Sverige drabbas ca 2800 kvinnor av gynekologisk cancer varje år. Det finns fem olika typer 
av cancer som drabbar kvinnans könsorgan: blygdläppar, slida, livmoder, äggledare och 
äggstockar. De tre vanligaste formerna är livmodercancer, äggstockscancer och 
livmoderhalscancer. Sjukdomsbilden varierar beroende på vilken typ av cancerform. 
Livmodercancer som ofta upptäcks tidigt är chansen till överlevnad stor medan 
äggstockscancer som är den mest aggressiva formen är svår att upptäcka i tidigt skede.  
 
Behandlingen innefattar nästan alltid kirurgi eller strålbehandling. Cellgifter och biologiska 
läkemedel har fått en mer och mer betydande roll. Antalet canceröverlevare har ökat i 
samhället tack vare ökad medelålder hos befolkning tillsammans med modern teknik, nya 
läkemedel och optimerade behandlingsregimer. Det innebär också att canceröverlevare lever 
längre cancerfria men tvingas samtidigt handskas med följdsjukdomar efter strålbehandling. 
En vanligt förekommande biverkning på strålbehandling är påverkan på tarmhälsan.    
 
Vår studie handlar om en grupp kvinnor med gynekologisk cancer som blivit strålbehandlade 
mellan år 1991 och 2003. De har följts upp 2-15 år efter strålbehandling med ett 
frågeformulär rörande deras hälsa.  Frågeformuläret besvarades även av en kontrollgrupp 
bestående av friska kvinnor med samma profil såsom ålder och boendeort. 28 symptom som 
nedsätter tarmhälsan efter strålbehandling har identifierats efter en sammanställning av 
formulären. Dessa 28 symptom kan grupperas in i fem distinkta syndrom som kallas för 
radiation-induced survivorship syndrome: läckagesyndrom, trängningssyndrom, svår 
slemutsöndring, okontrollerad flatulens samt anal blödning. 
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Syftet med denna studie är att förstå hur radiation-induced survivorship syndrom till följd av 
strålbehandling påverkar livskvalitet samt psykiska och kroppsliga hälsan hos 
canceröverlevare i jämförelse med friska populationen.  
 
Resultatet pekar på att samtliga fem radiation-induced survivorship syndrom; 
läckagesyndrom, trängningssyndrom, svår slemutsöndring, okontrollerad flatulens samt anal 
blödning är associerade med sämre självskattad livskvalitet, lägre psykiskt välbefinnande, 
sämre kroppslig hälsa och självkänsla jämfört med den friska populationen. Att leva med 
något av syndromen leder till en tredubblad ökad risk för sämre livskvalitet och fysisk hälsa. I 
undersökningen fann vi ingen skillnad i humöret, depression eller ångest är inte vanligare hos 
cancer överlevare i jämförelse med kontrollgruppen. 
 
Det finns många omdiskuterade teorier till varför tarmbesvär uppkommer efter strålning, men 
än idag råder det fortfarande oklarhet. Mängden stråldos, metod av strålbehandling, genetiska 
orsaker samt miljöfaktorer som t.ex. rökning och födoämnen tros vara bidragande orsaker. 
 
I dagsläget saknas effektiv behandling mot besvären som canceröverlevarna lider av. Det 
finns förslag i olika studier som visar behov av cancerrehabilitering i form av psykoterapi 
eller själasörjande samtal. Det finns även symptomlindrande behandling i form av 
inkontinensskydd vid läckage, volymökande medel och stoppande medel för normalisering av 
avföring samt specifika behandlingar som gallsyrahämmare. Trots den intensiva forskning 
som pågår idag, finns det fortfarande många kunskapsluckor och mycket kvar att lära för våra 
framtida canceröverlevare. 
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Appendix Six questions selected from the questionnaire” En undersökning om kvinnors hälsa 
efter strålbehandling vid en gynekologisk cancersjukdom”. Reproduced from Gail Dunberger 
et al. 
1.Hur har Din livskvalitet varit, det senaste halvåret? 
 – Sätt en ring runt den siffra som bäst stämmer in på Dig – 
1-------------2-------------3-------------4------------5--------------6-------------7 
Ingen livskvalitet alls                          Bästa möjliga livskvalitet 
 
 
2. Har Du känt Dig nedstämd eller deprimerad, det senaste halvåret? 
 – Sätt en ring runt den siffra som bäst stämmer in på Dig – 
  
1-------------2-------------3-------------4------------5--------------6-------------7 
Aldrig     Hela tiden 
 
 
3. Har Du känt oro eller ångest, det senaste halvåret?  
 – Sätt en ring runt den siffra som bäst stämmer in på Dig – 
 
1-------------2-------------3-------------4------------5--------------6-------------7 
Aldrig     Hela tiden 
 
 
4. Hur har Ditt psykiska välbefinnande varit, det senaste halvåret? 
 – Sätt en ring runt den siffra som bäst stämmer in på Dig – 
 
1-------------2-------------3-------------4------------5--------------6-------------7 
Inget välbefinnande                  Bästa tänkbara välbefinnande  
 
 
5. Hur har Din kroppsliga hälsa varit, det senaste halvåret? 
 – Sätt en ring runt den siffra som bäst stämmer in på Dig – 
 
1-------------2-------------3-------------4------------5--------------6-------------7 
Sämsta tänkbara hälsa                     Bästa tänkbara hälsa 
 
 
6. Hur har Din självkänsla varit, det senaste halvåret? 
 – Sätt en ring runt den siffra som bäst stämmer in på Dig – 
 
1-------------2-------------3-------------4------------5--------------6-------------7 
Ingen självkänsla                     Bästa tänkbara självkänsla 
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Supplementary table Presenting association between radiation-induced survivorship 
syndrome/without syndrome and QOL outcome among cancer survivors and control women. 
Bold indicates significant value. 
QOL outcome for 
each syndrome 
 
 
Control 
No./total 
no. (%) 
Cancer 
Survivors 
No./total  
no. (%) 
Survivors vs 
controls 
Age-Adjusted 
Relative risk 
 (95% CI) 
Survivors vs 
controls 
Unadjusted  
Relative risk  
(95%CI) 
Without syndrome     
Self-Assessed low QOL 16/213 (8) 16/200 (8) 1.4 (0.7-2.9) 1.1 (0.5-2.1) 
Feeling sad or 
depressed 
51/214 (24) 40/201 (20) 1.1 (1.0-1.2) 0.8 (0.6-1.2) 
Worry or anxiety 41/215 (19) 27/201 (13) 1.1 (1.0-1.2) 0.7 (0.5-1.1) 
Low psychological 
well-being 
28/213 (13) 21/200 (11) 0.7 (0.4-1.3) 0.8 (0.5-1.4) 
Self-Assessed poor 
physical health 
19/213 (9) 23/201 (11) 1.3 (0.7-2.4) 1.3 (0.7-2.3) 
Low self-esteem 18/210 (9) 18/201 (9) 1.2 (0.6-2.3) 1.0 (0.6-2.0) 
Urgency syndrome      
Self-Assessed low QOL 16/213 (8) 
 
67/323 (21) 2.9 (1.7-4.8) 2.8 (1.6-4.6) 
Feeling sad or 
depressed 
51/214 (24) 
 
99/323 (31) 0.9 (0.8-1.0) 1.3 (1.0-1.7) 
Worry or anxiety 41/215 (19) 
 
95/324 (29) 0.9 (0.8-1.0) 1.5 (1.1-2.1) 
Low psychological 
well-being 
28/213 (13) 
 
79/324 (24) 1.9 (1.2-2.8) 1.9 (1.2-2.8) 
Self-Assessed poor 
physical health 
19/213 (9) 
 
85/324 (26) 2.9 (1.8-4.7) 2.9 (1.8-4.7) 
Low self-esteem 18/210 (9) 61/324 (19) 2.3 (1.4-3.8) 2.2 (1.3-3.6) 
Leakage syndrome      
Self-Assessed low QOL 16/213 (8) 
 
58/265 (22) 2.9 (1.7-5.0) 2.9 (1.7-4.9) 
Feeling sad or 
depressed 
51/214 (24) 
 
78/263 (30) 0.9 (0.8-1.0) 1.2 (0.9-1.7) 
Worry or anxiety 41/215 (19) 
 
72/264 (27) 0.9 (0.8-1.0) 1.4 (1.0-2.0) 
Low psychological 
well-being 
28/213 (13) 
 
69/264 (26) 1.9 (1.3-2.9) 2.0 (1.3-3.0) 
Self-Assessed poor 
physical health 
19/213 (9) 
 
72/265 (27) 3.0 (1.9-4.9) 3.0 (1.9-4.9) 
Low self-esteem 18/210 (9) 51/265 (19) 2.3 (1.3-3.8) 2.2 (1.4-3.7) 
Excessive gas 
discharge 
    
Self-Assessed low QOL 16/213 (8) 
 
40/193 (21) 2.9 (1.6-4.9) 2.8 (1.6-4.8) 
Feeling sad or 
depressed 
51/214 (24) 
 
61/192 (32) 0.9 (0.8-1.0) 1.3 (1.0-1.8) 
Worry or anxiety 41/215 (19) 61/193 (32) 0.8 (0.8-1.0) 1.7 (1.2-2.3) 
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Low psychological 
well-being 
28/213 (13) 
 
47/192 (25) 1.9 (1.2-2.9) 1.9 (1.2-2.8) 
 
Self-Assessed poor 
physical health 
19/213 (9) 
 
53/194 (27) 3.1 (1.9-5.0) 3.1 (1.9-5.0) 
Low self-esteem 18/210 (9) 39/194 (20) 2.5 (1.5-4.2) 2.3 (1.4-4.0) 
Excessive mucus 
discharge  
    
Self-Assessed low QOL 16/213 (8) 
 
30/167 (18) 2.5 (1.4-4.5) 2.4 (1.3-4.2) 
 
Feeling sad or 
depressed 
51/214 (24) 
 
46/167 (28) 1.0 (0.8-1.1) 1.2 (0.8-1.6) 
Worry or anxiety 41/215 (19) 
 
41/167 (25) 0.9 (0.8-1.0) 1.3 (0.9-1.9) 
Low psychological 
well-being 
28/213 (13) 
 
35/167 (21) 1.6 (1.0-2.5) 1.6 (1.0-2.5) 
Self-Assessed poor 
physical health 
19/213 (9) 
 
41/167 (25) 2.8 (1.7-4.6) 2.8 (1.7-4.6) 
Low self-esteem 18/210 (9) 29/167 (17) 2.2 (1.2-3.8) 2.0 (1.2-3.5) 
Blood discharge      
Self-Assessed low QOL 16/213 (8) 
 
28/113 (25) 3.3 (1.9-5.9) 3.3 (1.9-5.8) 
Feeling sad or 
depressed 
51/214 (24) 
 
39/113 (35) 0.9 (0.7-1.0) 1.4 (1.0-2.1) 
Worry or anxiety 41/215 (19) 
 
34/114 (30) 0.9 (0.8-1.0) 1.6 (1.1-2.3) 
Low psychological 
well-being 
28/213 (13) 
 
34/114 (30) 2.2 (1.4-3.5) 2.3 (1.5-3.5) 
Self-Assessed poor 
physical health 
19/213 (9) 
 
38/114 (33) 3.7 (2.2-6.2) 3.7 (2.3-6.2) 
Low self-esteem 18/210 (9) 26/114 (23) 2.7 (1.5-4.7) 2.7 (1.5-4.6) 
 
